Homoeopathic Treatment of Nasal Allergy: A Clinical Trial

INTERVENTION: Intervention1: Individualized homoeopathic medicines: Individualized homoeopathic medicines prescribed according to classical homoeopathic principles, based on the patient s constitutional characteristics or the acute totality of symptoms. The medicines are administered orally. All the medicinal dilutions will be procured from a Good Manufacturing Practice certified homoeopathic pharmaceutical company and will be dispensed in 30 size sugar globules, each dose comprising of 4 pills. The medicines will be prescribed in centesimal potencies like 6C, 30C, 200C, 1M as per the requirement of the case and repetition will be done following the homoeopathic principles. Control Intervention1: Placebo: placebo is dispensed as 30 size sugar globules undifferentiated from the IHM to the naked eye, each dose comprising of 4 pills, given twice daily. CONDITION: Health Condition 1: J309‐ Allergic rhinitis, unspecified PRIMARY OUTCOME: Changes in mean Total Nasal Symptom Score ; Change in mean serum Ig E levelsTimepoint: Changes in mean Total Nasal Symptom Score from baseline to sixth month, at monthly intervals ; Change in mean serum Ig E levels from baseline to sixth month SECONDARY OUTCOME: Changes in absolute eosinophil count between the two groupsTimepoint: from baseline to sixth month Comparing the quality‐of‐life questionnaire RQLQ scores between interventional and placebo groupsTimepoint: at three monthly intervals To compare the usage of rescue medication between the two groupsTimepoint: at the end of follow‐up i.e., at si Xmonths. INCLUSION CRITERIA: Participants with a history of an allergic cause and one or more of the following symptoms, like episodic rhinorrhoea, sneezing, obstruction of the nasal passages with lachrymation, post‐nasal discharge, and pruritus of the nasal mucosa, conjunctiva, and oropharynx, together with the anterior rhinoscopic findings of pinkish grey pale, boggy mucosa covered with a thin glistening mucous and hypertrophied turbinates. Presence of moderate to severe symptoms as per ARIA classification and TNSS with a score of 5‐12. Participants with elevated serum IgE levels of more than 120 IU/ml Voluntary written informed consent.